Mylan Labs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs

MYL 15.86

0.0%

Nov 19 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Druggist who wrote (320)	6/3/1998 10:59:00 AM
From: David Lawrence	Read Replies (1) of 384

Mylan Announces Approval on Generic Plaquenil ====================================================================== PITTSBURGH--(BUSINESS WIRE)--June 3, 1998--Mylan Laboratories Inc. (NYSE:MYL) announced today that it has received approval from the Food and Drug Administration to manufacture and market Hydroxychloroquine Sulfate tablets USP, 200mg. This product is the generic equivalent of Sanofi Winthrop Pharmaceuticals' Plaquenil(R), which is indicated for the suppressive treatment and treatment of acute attacks of malaria. It is also indicated for the treatment of lupus erythematosus and rheumatoid arthritis. The product will be manufactured in Morgantown, West Virginia. Shipment will begin shortly.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next